PROFILPELAJAR.COM

ADX71441
Names
	IUPAC name N-[5-[4-[(4-chloro-3-fluorophenyl)methyl]-6-methoxy-3,5-dioxo-1,2,4-triazin-2-yl]-2-fluorophenyl]acetamide
Identifiers
CAS Number	1207440-88-7;
3D model (JSmol)	Interactive image;
PubChem CID	25106292;
	InChI Key: BQDMEJYNGXEHSW-UHFFFAOYSA-N; InChI=1S/C19H15ClF2N4O4/c1-10(27)23-16-8-12(4-6-14(16)21)26-19(29)25(18(28)17(24-26)30-2)9-11-3-5-13(20)15(22)7-11/h3-8H,9H2,1-2H3,(H,23,27);
	SMILES CC(=O)NC1=C(C=CC(=C1)N2C(=O)N(C(=O)C(=N2)OC)CC3=CC(=C(C=C3)Cl)F)F;
Properties
Chemical formula	C19H15ClF2N4O4
Molar mass	436.80 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

ADX-71441 is a GABA_B receptor positive allosteric modulator currently being investigated as a potential treatment for anxiety, epilepsy, pain and other conditions.

Therapeutic potential

ADX-71441 has been shown to reduce alcohol consumption.^[1] This result was observed in both alcohol dependent and non-dependent animals.^[2]^[3]

There were also trials about nicotine addiction, which showed positive results: ADX-71441 was able to decrease some withdrawal symptoms of nicotine withdrawal.^[4]

This compound has also been shown to reduce anxiety in people with PTSD.^[5]

Experiments have shown that this compound was able to decrease hypersensitivity to pain in mice, Guinea pigs and rats.^[5]

ADX-71441 has been shown to have less tolerance and side effects than direct GABA_B agonists, such as baclofen.^[2]

^ "Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence". Addex therapeutics. Retrieved 2024-02-03.
^ ^a ^b Augier E, Dulman RS, Damadzic R, Pilling A, Hamilton JP, Heilig M (August 2017). "The GABA_B Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats". Neuropsychopharmacology. 42 (9): 1789–1799. doi:10.1038/npp.2017.53. PMC 5520784. PMID 28294133.
^ Colombo G (March 2024). "Positive allosteric modulators of the GABA_B receptor: a new class of ligands with therapeutic potential for alcohol use disorder". Alcohol and Alcoholism. 59 (3). Oxford, Oxfordshire. doi:10.1093/alcalc/agae018. PMID 38566580.
^ "Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction". Addex therapeutics. Retrieved 2024-02-03.
^ ^a ^b Kalinichev M, Girard F, Haddouk H, Rouillier M, Riguet E, Royer-Urios I, et al. (March 2017). "The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABA_B receptor with a potential for treatment of anxiety, pain and spasticity". Neuropharmacology. 114: 34–47. doi:10.1016/j.neuropharm.2016.11.016. PMID 27889489. S2CID 36606154.